Memantine Teva (Memantine)

Memantine works as a non‑competitive antagonist of NMDA receptors. By blocking excessive calcium entry through these receptors, it limits glutamate‑induced excitotoxicity, helping to protect neurons and slow the progression of cognitive decline in Alzheimer's disease.

The appropriate dose of Memantine Teva is determined by the prescribing clinician based on the patient’s condition, renal function, and response to therapy. Dosage adjustments are made individually and should follow the prescriber’s instructions.

The safety of memantine in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Memantine belongs to the NMDA receptor antagonist class, whereas many other Alzheimer's drugs are acetylcholinesterase inhibitors. Memantine is typically used in moderate to severe stages and can be combined with an inhibitor for added benefit, offering a different mechanism of neuroprotection.

Memantine Teva should be stored at ambient temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture, heat and direct sunlight to maintain product stability.

Memantine Teva is taken orally, usually once daily after a meal to improve tolerability. The tablet should be swallowed whole with water and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious risks include the potential for seizures, severe skin reactions such as Stevens‑Johnson syndrome, cardiac arrhythmias, hepatic dysfunction, and emergence of suicidal thoughts. Patients should be monitored closely for any of these events.

Memantine is contraindicated in patients with known hypersensitivity to memantine or any of the tablet’s excipients. Caution is advised in individuals with severe renal impairment, uncontrolled epilepsy, or those taking other NMDA antagonists.